Pharmaceutical Composition Comprising Factor VII Polypeptides and TAFI Polypeptides

Abstract

The present invention relates to a composition comprising factor VII or a factor VII-related polypeptide, and TAFI or a TAFI-related polypeptide, and the use thereof for treating bleeding episodes.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This patent application is a Divisional of copending U.S. application Ser. No. 10 / 290,814 filed Nov. 8, 2002 notice of Allowance mailed Jun. 29, 2007). This patent application claims the benefit of U.S. Provisional Patent Application No. 60 / 333,672 filed Nov. 27, 2001 and Danish Patent Application No. PA 2001 01664, filed Nov. 9, 2001.FIELD OF THIS INVENTION [0002] The present invention relates to a pharmaceutical composition comprising factor VII or a factor VII-related polyp eptide and TAFI or a TAFI-related polyp eptide. The invention also relates to the use of a combination of a factor VII or a factor VII-related polyp eptide and a TAFI or a TAFI-related polyp eptide for the manufacture of a medicament for treatment of subjects suffering from bleeding episodes, or prevention hereof. The invention also relates to a method for treatment of bleeding episodes in subjects and to a method for enhancing clot formation in a subject. The pre...

AI Technical Summary

Benefits of technology

[0016] One object of the present invention is to provide compositions, which can effectively be used in the treatment or prophylaxis of bleeding episodes and coagulation disorders.

[0017] A second object of the present invention is to provide compositions in single-unit dosage form, which can effectively be used in the treatment or prophylaxis of bleeding episodes or as a procoagulant. Another object of the present invention is to provide compositions, methods of treatment or kits exhibiting a synergistic effect.

[0018] A further object of the present invention is to provide compositions, methods of treatment or kits exhibiting no substantial side effects, such as a high level of systemic activation of the coagulation system.

Problems solved by technology

However, also moderate bleedings requiring the administration of human blood or blood products (latelets, leukocytes, plasma-derived concentrates for the treatment of coagulation defects, etc.) may lead to complications associated with the risk of transferring human viruses (hepatitis, HIV, parvovirus, and other, by now unknown viruses).

Extensive bleedings requiring massive blood transfusions may lead to the development of multiple organ failure including impaired lung and kidney function.

Once a subject has developed these serious complications a cascade of events involving a number of cytokines and inflammatory reactions is started making any treatment extremely difficult and unfortunately often unsuccessful.

Images